Fly News Breaks for November 13, 2019
Nov 13, 2019 | 11:47 EDT
JPMorgan analyst Tycho Peterson said Adaptive Biotechnologies' "solid" Q3 results, guidance raise and confirmation of the first clinical signal in acute Lyme disease for immunoSEQ Dx leave him maintaining his view of the company "as a best-in-class asset in the rapidly-emerging, immune-driven medicine market." He still sees potential upside for the stock from current levels despite a strong rally of 42% in shares since the company's IPO, added Peterson, who keeps an Overweight rating and $45 price target on Adaptive shares.
News For ADPT From the Last 2 Days
There are no results for your query ADPT